Public Health Vaccines LLC
A US-based vaccine development company awarded $1.9m by CEPI on 9 June 2026 to generate master viral seed stock for a fourth Bundibugyo ebolavirus vaccine candidate on the rVSV platform.
Last refreshed: 16 June 2026 · Appears in 1 active topic
What stage is Public Health Vaccines at and when could a Bundibugyo vaccine reach trials?
Timeline for Public Health Vaccines LLC
Received $1.9m CEPI award to generate rVSV master seed stock for a Bundibugyo vaccine candidate
Pandemics and Biosecurity: CEPI funds a fourth Ebola vaccine- Who is Public Health Vaccines and what Ebola vaccine are they making?
- Public Health Vaccines LLC is a US-based vaccine developer. In June 2026 it received $1.9m from CEPI to generate master viral seed stock for a Bundibugyo ebolavirus vaccine candidate using the rVSV platform, the same technology behind the licensed Zaire Ebola vaccine Ervebo.Source: CEPI award announcement
- How many Ebola vaccines is CEPI funding in 2026?
- After the June 2026 award to Public Health Vaccines, CEPI is funding four Bundibugyo ebolavirus vaccine candidates across three platforms (rVSV, ChAdOx1, and mRNA), totalling approximately $63.7 million. The four developers are Public Health Vaccines, IAVI, Serum Institute of India, and Moderna.Source: CEPI award announcement
- How long does it take to develop an Ebola vaccine from seed stock to human trials?
- Master viral seed stock is the first manufacturing bottleneck. From seed stock to a Phase 1 safety trial typically takes many months of cell-culture establishment and quality testing, before any human dosing begins. A licensed vaccine is many years further beyond that.Source: CEPI award announcement
Background
Public Health Vaccines LLC received a $1.9 million award from CEPI on 9 June 2026 to generate master viral seed stock for a fourth Bundibugyo ebolavirus vaccine candidate on the rVSV platform. The award brings CEPI's total Bundibugyo vaccine portfolio to four candidates across three platforms, totalling approximately $63.7 million in commitments. The company is at the master viral seed stage, before Phase 1 human trials; generating a reliable seed stock is the foundational bottleneck that can ADD months to a vaccine timeline if not funded early.
The rVSV platform (recombinant vesicular stomatitis virus) uses a harmless livestock virus engineered to carry the target pathogen's immune markers. It is the same technology behind Merck's Ervebo, the only licensed Zaire ebolavirus vaccine. Public Health Vaccines is one of four organisations in CEPI's current Bundibugyo portfolio alongside IAVI, Serum Institute of India (manufacturing the Oxford ChAdOx1 candidate), and Moderna (mRNA platform).
Public Health Vaccines LLC is a US-based entity, placing it within the broader CEPI portfolio that spans Norwegian, Indian, and American developers. Its work sits at the earliest pre-clinical stage as of the June 2026 award, and the PATH from master seed stock to a licensed product runs through Phase 1 safety trials, Phase 2 efficacy studies, regulatory review, and manufacturing scale-up. The award does not imply imminent human trials, but funding the seed stock now shortens the critical PATH if the Bundibugyo outbreak continues.
